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Abstract
The North American Prodrome Longitudinal Study (NAPLS) is a consortium of eight programs
focusing on the psychosis prodrome. Funded by the National Institute of Mental Health (NIMH),
the sites are located at Emory University, Harvard University, University of Calgary, UCLA,
UCSD, University of North Carolina Chapel Hill, Yale University, and Zucker Hillside Hospital.
Although the programs initially developed independently, they previously collaborated to combine
their historical datasets and to produce a series of analyses on predictors of psychosis in one of the
largest samples of longitudinally followed prodromal subjects worldwide. This led to the
development of a five year prospective study “Predictors and Mechanisms of Conversion to
Psychosis”, (also known as NAPLS-2) with three major aims: (1) to prospectively test the
prediction algorithm developed in NAPLS-1, (2) to investigate the neuroanatomical,
neurophysiological, neurocognitive, and neurohormonal factors that may contribute to the
development of psychosis, and (3) to develop a repository of DNA, RNA, and plasma from
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participants meeting diagnostic criteria for a clinical high risk (CHR) state and from
demographically similar healthy subjects. Funded by NIMH in 2008, NAPLS-2 will generate the
largest CHR for psychosis sample with 720 CHR and 240 healthy comparison subjects, and thus
will provide statistical power and scientific scope that cannot be duplicated by any single site
study. This paper describes the overall methodology of the NAPLS-2 project and reports on the
ascertainment and demographics at the midway point of the study with (360 CHR) and 180
controls.
1. INTRODUCTION
Interest in early detection and prevention of schizophrenia and other psychotic disorders
stems from evidence of brain structural changes and decline in function around the time of
psychosis onset, suggesting that the pre-onset or ‘prodromal’ period affords a window of
opportunity for preventive intervention. Identifying predictors and mechanisms of
conversion to psychosis among such individuals ascertained to be in a clinical high risk
(CHR) or prodromal clinical state are critical steps in the search for preventive strategies.
Achieving these aims requires sample sizes much larger than those typically available at a
single research centre within a reasonable time period.
The North American Prodrome Longitudinal Study (NAPLS) is a consortium of eight
programs focusing on the psychosis prodrome. The sites are located at Emory University,
Harvard University, University of Calgary in Canada, University of California at Los
Angeles, University of California at San Diego, University of North Carolina at Chapel Hill,
Yale University, and Zucker Hillside Hospital. In a prior phase of the project, these sites
collaborated to combine previously collected datasets and produced a series of analyses on
predictors of psychosis in the largest sample of longitudinally followed prodromal subjects
worldwide (N=291) (Addington et al., 2007). Results of these analyses indicated that risk for
the onset of psychosis in this population was 35% after 2 ½ years of follow-up, with a
decelerating rate of conversion over this period. The NAPLS data set was used to derive a
psychosis prediction algorithm with high positive predictive power (~80%), but only modest
sensitivity (~40%).(Cannon et al., 2008) The published prediction algorithm included
genetic risk (having a first degree relative with a psychotic disorder and functional decline),
more severe unusual thought content, and greater social impairment.
These preliminary efforts led to a five year prospective study “Predictors and Mechanisms
of Conversion to Psychosis”, funded by NIMH in 2008, also referred to as NAPLS 2 that
included all eight NAPLS sites. The number of subjects in NAPLS 2 is anticipated to be
sufficient to address fundamental questions about the neurobiological correlates of the
development of psychosis. The goal of recruiting a sample of 720 clinical high risk
participants and 240 healthy controls will be achieved by the end of 2012, and based on the
previously collected NAPLS 1 data, a conversion rate of approximately 30% is expected
with up to two year follow-up.
This paper describes the overall methodology of the NAPLS 2 project and reports on the
ascertainment and demographics of the first half of the CHR sample (N=360) and 180 of the
healthy controls.
2. AIMS OF THE PROJECT
The central pathophysiologic assumption underlying the project is that schizophrenia (and
other psychotic disorders) reflect a process of brain volume reduction involving pruning of
synapses and dendrites, that result in reduced cortical connectivity (McGlashan and
Hoffman, 2000), particularly in prefrontal and superior and medial temporal lobe regions
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governing attention, executive, auditory-language, and memory-related functions. The first
project aim is to determine whether the NAPLS 1 psychosis risk prediction algorithm can be
replicated in a new and larger sample of CHR individuals. The hypothesis is that each of
four factors: genetic vulnerability to schizophrenia with recent deterioration in functioning,
higher levels of unusual thought content, higher levels of suspicion-paranoia, greater social
impairment at baseline, will independently predict a higher risk for conversion to psychosis,
and that combining all of these indicators will substantially reduce false positive psychosis
predictions over two years of follow-up. The second is to determine whether biological and
neurocognitive abnormalities preceding psychosis onset contribute to predicting psychosis
independently of the clinical algorithms and whether they can be combined with the clinical
measures to enhance predictive utility.
The third aim is to determine whether neuroanatomical, neurophysiological, neurocognitive,
and neurohormonal abnormalities that precede psychosis represent stable vulnerability
markers or markers of progression during the prodromal phase. This will enable us to
determine whether CHR individuals who convert to psychosis show a steeper rate of change
in neurobiological risk indicators compared to non-converters and healthy controls. The
final aim is to develop a repository of DNA and RNA from participants meeting diagnostic
criteria for a CHR state and from demographically similar healthy participants.
3. NAPLS TASK FORCES
In NAPLS each site contributes an area of uniqueness to the domain of assessment. The
Clinical Task Force is led by J. Addington (Calgary) and consists of psychodiagnostics (JA
& TMcG), psychopathology (JA) and early risk factors (JA). The Social Task Force is led
by B. Cornblatt (Zucker Hillside Hospital (ZHH)) with a focus on social and role
functioning (BC) and social cognition (JA). Neuropsychology is directed by L Seidman
(Harvard). Treatment is monitored by S. Woods (Yale). Neuroimaging is directed by T.
Cannon (UCLA). The electrophysiology Task Force is co-chaired by K. Cadenhead (UCSD)
and D. Mathalon (UCSF). E. Walker (Emory) is the chair of the Stress Hormone Task Force.
D. Perkins (UNC) and M. Tsuang (UCSD) co-chair the Genomics Task Force.
The task force chair(s) were responsible for developing and coordinating each aspect of the
study protocol including ongoing training and quality assurance procedures in all
assessments. Rigorous protocols for training, standardization of procedures and maintenance
of reliability have been applied across all sites by each task force. Following the initial
startup, annual meetings to monitor quality assurance have been convened.
4. ASSESSMENTS
The clinical component of the project attempts to replicate and refine the major NAPLS 1
prediction findings. The biomarkers component tests potential mechanisms of illness onset
and/or progression in the neuroanatomical, electrophysiological, neurohormonal,
neuropsychological, and genomic domains. Selection of measures attempted to reflect both
vulnerability-related and progressive neuromaturational processes. Selection was limited to
measures for which evidence existed with relevance to the psychosis prodrome, and which
were likely to reflect pathophysiologic changes associated with clinical and/or functional
deterioration.
We required proven methods for the reliable collection and aggregation of data across
measurement points and across sites. The selected measures span multiple critical levels of
analysis (i.e. genomic, hormonal, anatomical, physiological and behavioral). Such a multi-
level perspective was assumed to be necessary given that the aberrant molecular and cellular
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processes underlying psychotic disorders were likely to reflect cascading influences across
these five critical domains.
Baseline only measures include demographics, premorbid functioning, life events and
childhood trauma. Six monthly clinical assessments include SIPS, anxiety, depression,
substance use and social functioning. Logs of medications, psychosocial treatments and
resource utilization are updated every 6 months. Biomarker assessments of neurocognition,
electrophysiology, cortisol, blood draws, and imaging occur at baseline, 1 and 2 years.
Should a participant convert to psychosis, then the complete assessment is done at the time
of conversion with a one year post conversion assessment to determine the diagnosis.
5. ASCERTAINMENT
NAPLS participants are help-seeking. They are referred from health care providers,
educators, or social service agencies or they self-refer in response to intensive community
education efforts. These initiatives included academic detailing, grand rounds, educational
talks, mailings, postings, websites and internet hits, and public service announcements. Each
site has developed extensive referral sources in their area, and routinely contact them
personally, with mail outs, and through educational efforts. Potential participants undergo a
telephone screen. Those who screen positive are invited to an in-person eligibility and
consent evaluation.
The first half of the sample N=360 was recruited over a 2 year period from January 2009
until January 2011. Overall, 1749 referrals were received as depicted in Figure 1. Based on a
phone screen 618 clearly did not meet CHR criteria, but 52% were found to be suitable for a
screening interview. Of those deemed not suitable at screening some were psychotic.
Examples of other reasons included not having prodromal symptoms, calling about other
problems such as anxiety, depression, severe autism, non-English speaking, or outside the
age range. Of those offered screening, 28% did not keep their scheduled interview and 28%
were found not to meet CHR criteria. Examples of reasons for not meeting criteria at the
assessment included prodromal symptoms being longstanding, not frequent enough or no
longer present. Outcome of all referrals are presented in Figure 1. There were some site
differences. Yale and ZHH received significantly more referrals and ruled out more at phone
screening. UNC had a higher proportion of referrals that they were unable to contact further.
San Diego, Emory and Yale had a higher proportion of no shows.
Figure 2 depicts the referral sources and the number meeting prodromal criteria from each
source. Overall, significantly more referrals came from self and family, although the
majority of such referrals did not meet criteria. UCLA, Harvard, UCSD and Calgary
recruited from a wide range of clinical and community services. Although Yale did receive
some referrals from clinical services the majority of Yale’s were self-referrals. Referrals for
ZHH were made primarily by the outpatient department intake staff and other clinical
services that informed parents to contact the program directly. The majority of the referrals
at Emory and UNC were self-referrals, followed by family and friends.
Figure 3 elaborates on the marketing strategies and their effectiveness. Presentations and
web and internet searches seemed to be the most successful, as was “word of mouth”. This
was the case at most of the sites; the one exception being Emory where the majority of the
referrals resulted from advertising in public places.
6. SAMPLE
The clinical high risk sample met the Criteria of Prodromal Syndromes (COPS) which is
based on the Structured Interview for Prodromal Syndromes (SIPS).(McGlashan et al.,
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2010) After a comprehensive assessment that includes administering the Structure Clinical
Interview for DSM-IV (SCID) (First et al., 1995) and the SIPS, vignettes are developed for
each CHR participant for the purpose of obtaining a consensus diagnosis. The attenuated
psychotic symptoms rated on the Scale of Prodromal Symptoms (SOPS) are described at
length and include both recent and longstanding symptoms. The vignette is written so that
another rater can review the information under each symptom category and provide a
reliable rating. Once approved at the site level, the vignette is presented on a conference call
for a consensus decision on the symptom ratings as well as the diagnosis. The NAPLS-2
consensus call, chaired by JA, is held once a week and is attended by members of each of
the eight study sites including the authors of the SIPS, Drs McGlashan and Walsh, who act
as co-chairs. Submitted vignettes are individually reviewed and a consensus must be reached
on each symptom rating, diagnosis and ultimate admission into the study. It is often
challenging making differentiations with respect to some of the exclusion criteria listed
below. But we use our calls to discuss issues such as the impact of substance abuse and use
of antipsychotics. Such decisions can later be reviewed when we have followed the sample
and determined the outcome of the participants in terms of conversion and remission.
Cross-site reliability in the ratings of the SOPS, was conducted on a yearly basis using a new
videotape each year. Ratings from all raters at all sites were compared to “gold standard”
ratings on the SOPS. Intra class correlations, over three years, for the total SOPS scores
ranged from 0.82 to 0.93 and for the attenuated positive symptom score from the SOPS
ranged from 0.92–0.96. There were minimal differences across the individual sites. All
interclass correlations were in the excellent range.
6.1 Inclusion and exclusion criteria
Those at CHR had to be between 12 and 35 years old and meet diagnostic criteria for a
prodromal syndrome as per the COPS criteria (McGlashan et al., 2010) or if under 19 meet
criteria for schizotypal personality disorder (SPD). Participants were excluded if they met
criteria for current or lifetime Axis I psychotic disorder, including affective psychoses, IQ >
70, or had a past history of a central nervous system disorder, or substance dependence in
the past 6 months or the diagnostic prodromal symptoms were clearly caused by an Axis 1
disorder. Other non-psychotic DSM-IV disorders were not exclusionary (e.g. substance
abuse disorder, major depression, anxiety disorders, Axis II disorders), as long as the
disorder did not account for the individual’s prodromal symptoms. Use of antipsychotics
was not an exclusion provided there was clear evidence that prodromal but not psychotic
symptoms were present when the medication was started. Control subjects could not meet
criteria for any prodromal syndrome, any current or past psychotic disorder or a Cluster A
personality disorder diagnosis, not have a family history (in first-degree relatives) of any
psychotic disorder or any other disorder involving psychotic symptoms. They could not be
currently using psychotropic medication.
6.2 Demographics
The samples’ age ranges from 12–34 years with a mean (SD) age of 18.99 (4.18) for CHR
and 19.54 (4.77) for healthy controls (HC). There are significantly more males in the CHR
group (211, 58.6% vs 87, 48.3%, χ2 = 5.12, p<0.05). The groups did not differ in ethnicity
with the majority being white (CHR 55%, HC 59%) or marital status with the majority
(85%) being single or living at home (CHR 75%, HC 63%) or enrolled as a student (CHR
80.3%, HC 82.2%). Significantly more of the controls were working (46% vs 28%, χ2 =
13.97, p<0.05) and had significantly more years of education (12.39, SD=3.60 vs 11:56
SD=2.63, t=3.09, p<0.01). This may reflect the clinical nature of the sample. In addition the
majority of all participants were born in the USA or Canada. Eighty percent of CHR and
93% of control participants had English as their first language. Spanish was the first
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language of 50% of the non-English speaking group. We attempted to frequency match the
groups on age and gender.
6.3 Clinical presentation
The CHR participants are a help-seeking sample and as such present not only with
subthreshold symptoms but also a wide range of comorbidity. The majority (80%) meet
criteria for the attenuated positive symptoms syndrome with a small proportion meeting
another criteria or a combination of criteria. These CHR subtype diagnoses are presented in
Table 1. Table 2 reports on the diagnoses that differentiated the CHR from the control
group. Although the substance diagnoses for cannabis in particular appear low these are
individuals that meet diagnoses for abuse and/or dependence. For cannabis approximately
30% of the controls and 40% of the CHR rated themselves as current users.
6.4 Site differences
We compared the demographics across sites to assess heterogeneity. There were differences
for the CHR in age, years of education and gender. ZHH followed by UCLA had the
youngest participants with Emory having the oldest. ZHH had significantly younger
participants than Emory, UNC, San Diego and Yale and UCLA had significantly younger
participants than Emory. Related to age, participants at ZHH had significantly fewer years of
education than participants from Emory, UNC and UCSD. UCLA participants had fewer
years of education compared to UNC. Harvard, Emory and UNC had equal numbers of
males to females. Ratios of males to females at the other sites ranged from 70:30 to 62:38.
With respect to racial background, Emory had significantly more African American
participants than any other site at 50% with UCSD and Calgary having the least. Most sites
had 40–60% white participants with there being 65% at UNC and 75% at Calgary.
7. DATA MANAGEMENT
One concern with large multisite, longitudinal studies including many assessments is data
integrity. Data are managed at the Calgary site through a centralized Oracle database. Sites
can remotely manage both the input of participant study data and also track participant
protocol adherence and staff task management. Data input is strictly controlled with data
validation prior to saving and a two-step forced resolution of required data. No data can be
submitted until missing data fields are flagged with either reasons for absence or with a pre-
determined code. Prior to forcing a second blind double entry of all the data, all missing data
reasons must be validated and signed off with an acceptance code by a data manager from
the site. This rigorous feedback loop ensures better data collection, near perfect data entry
and much better data quality assurance. These codes can then be reported and reviewed by
the appropriate Task Force to determine further action. The system produces numerous
reports. These are used to track recruitment, dropout rates, data collection and consequent
data entry completion levels. Furthermore, it can measure the utility and validity of
measures and the protocol. This allows the data cleanup process to be continuous. There is
an overall data manager at the Calgary site with each site having their own data manager to
work with both within and across site data.
8. DISCUSSION
NAPLS-2 will be the one of the largest cohort studies of young people at clinical high risk
for psychosis to be followed longitudinally. It will be the first to study all of these clinical
and biological factors prospectively and simultaneously in a large and well-characterized
sample. This paper has described the aims and methods of the project and reported on
recruitment and preliminary descriptive data from the first half of the sample. The
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recruitment practices are similar across most of the sites. There are very few significant site
differences in samples and no-one site differs on more than one variable. Yet one of the
advantages of having multiple sites is that they are diverse with respect to the regions and
ethnicities represented. Our multi-site approach affords the opportunity to examine regional
and ethnic differences in the ascertainment of CHR individuals, as well as the nature and
course of prodromal syndromes. Further, by having multiple sites, we are able to validate
our measures across a range of clinical research facilities, and this has important benefits
with respect to establishing the generalizability of NAPLS findings, especially those that
bear on prediction algorithms Future reports will focus on baseline clinical and biological
characteristics, longitudinal changes and eventually predictors of conversion.
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Outcome of All Referrals to NAPLS
Addington et al. Page 8












Addington et al. Page 9












Addington et al. Page 10



















Addington et al. Page 11
Table 1
Prodromal Diagnostic Criteria
Criteria Percent of total
Attenuated positive symptoms (APS) 80.2
Genetic risk and deterioration (GRD) 4.7
Brief Intermittent positive symptoms (BIPS) 0.4
APS & GRD 9.3
APS & BIPS 1.9
BIPS & GRD 0
APS & GRD & BIPS 0
Under 19 plus schizotypy 4.4
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Table 2
SCID diagnoses
SCID-IV Diagnosis Clinical High Risk (N=360) Control (N=108) Significance of χ2
Depression- Current 41.4% 1.7% <0.0001
Depression- Lifetime 35.1% 5.6% <0.0001
Lifetime Alcohol 10.7% 1.1% <0.0001
Current Cannabis 5.8% 1.1% <0.05
Lifetime Cannabis 12.8% 2.8% <0.001
Current OCD 7.8% 0% <0.0001
Lifetime OCD 4.6% 0% <0.01
Current PTSD 2.6% 0% <0.05
Lifetime PTSD 4.1% 0% <0.01
Current Panic 13.3% 0.6% <0.0001
Lifetime Panic 9.3% 0% <0.0001
Current Social Phobia 13.6% 0% <0.0001
Lifetime Social Phobia 7.5% 0.6% <0.0001
Current Specific Phobia 11.0% 0% <0.0001
Lifetime Specific Phobia 6.4% 0.6% <0.01
Current GAD or NOS 20.3% 2.2% <0.0001
Lifetime GAD or NOS 9.0% 0.6% <0.001
Current Attention- Deficit/Hyperactivity 15.7% 1.7% <0.0001
Lifetime Attention- Deficit/Hyperactivity 10.8% 2.2% <0.01
Current Learning Disorder NOS 2.3% 0% <0.05
Current Avoidant 10.4% 0% <0.0001
Lifetime Avoidant 4.6% 0% <0.01
Current Schizotypal 18.3% 0% <0.0001
Lifetime Schizotypal 7.2% 0% <0.0001
Current Borderline 3.8% 0% <0.01
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